A scoping review of 17 studies covering 2,790 chronic-urticaria patients mapped 60 urticaria-related adverse reactions (2.2% of the assembled population). Timing ranged from minutes to one week, with heterogeneous severity.
Key findings
- Phenotypes ranged from transient flares and injection-site plaques to angioedema, anaphylaxis-like and serum-sickness-like events, occurring after first, repeated or escalated doses. Management ranged from observation to discontinuation and systemic treatment.
Why this matters globally
Mapping timing, phenotype and rechallenge provides a basis for standardised biologic-safety reporting and for distinguishing disease flare from true drug hypersensitivity.
Thai researcher contribution
Researchers from Walailak University and Chaophya Abhaibhubejhr Hospital led the review with a Bhutanese clinician, contributing regional pharmacovigilance expertise.
Limitations to consider
A scoping review is not designed for pooled incidence or comparative certainty. Heterogeneous definitions prevent firm conclusions on causality, recurrence and rechallenge safety.
Verify the original sources
LifeRead the original article↗DOI: 10.3390/life16071124